|Videos|October 11, 2016
Evidence and Outcomes in Atopic Dermatitis
Advertisement
Episodes in this series
Panelists Peter L. Salgo, MD; Jeffrey D. Dunn, PharmD, MBA; Ed Pezalla, MD, MPH; Jonathan Silverberg, MD, PhD, MPH; and Cheryl Allen, BS Pharm, MBA, provide insight on the evidence and outcomes in atopic dermatitis and how they impact coverage.
Advertisement
Related to this article
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Category 1 placement for belantamab mafodotin plus bortezomib and dexamethasone puts guideline support ahead of the FDA label.
No new vouchers have been awarded since former FDA Commissioner Marty Makary left the agency in May, though HHS maintains the pilot is ongoing.
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Nicole Albanese, PharmD, explains how a structured testing schedule and simple notes help patients bring useful glucose data to their care team.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
3
Glucose Monitoring: Timing Makes Every Reading Count
4
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
5